CompletedNot Applicable

Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia

281 participantsStarted 2015-05

Plain-language summary

Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice. MRD results will be relate to treatment outcome and survival analysis variables (Overall Survival, Disease Free Survival, Cumulative Incidence of Relapse)

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Acute Myeloid Leukemia * Age \> 18 years * Intensive chemotherapy as first line curative treatment * Observation period: March 2004 - September 2014 * Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry performed at baseline * Written informed consent Exclusion Criteria: * Diagnosis of Acute Promyelocytic Leukemia * Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry NOT performed at baseline * Patient ineligible to intensive chemotherapy

What they're measuring

Response

Timeframe: +28 days after End of induction chemotherapy - Before Allogeneic Transplant, average of 3 to 6 months from beginning of therapy

Trial details

NCT IDNCT02714790

SponsorA.O.U. Città della Salute e della Scienza

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-06

View on ClinicalTrials.gov More Acute Myeloid Leukemia trials